December 18, 2024

Running out of letters

Hi there, 

Databricks raised a $10B Series J at a $62B valuation this week. 

That’s up from its $43B valuation a year ago. 

Here’s where it ranks among the top-valued startups globally: 

1. SpaceX ($350B valuation)

2. ByteDance ($300B)

3. OpenAI ($157B)  

4. Stripe ($70B)

5. SHEIN ($66B)

6. Databricks ($62B) 

7. xAI ($50B)

8. Revolut ($45B)

9. Canva ($32B)

10. Fanatics ($31B)

Below, we highlight CBI x Copilot, the rise of AI unicorns, the most promising digital health companies, and more.

Insights that live where you work

CB Insights market intelligence is now available in Microsoft Copilot. 

Revealed at Microsoft Ignite, our market intelligence can be woven right into the answers Copilot generates and the docs it creates. 

This means that the insights belong to everyone in a company so that they can be the smartest, fastest version of themselves.

Also, ngl, it was very exciting to see our Microsoft collaboration highlighted during a main stage keynote. A huge thank you to Nicole Herskowitz for the 🔥 demo. 

Get more details on how to use CB Insights in Microsoft Copilot here.

Fast unicorns

For AI startups, less is more.

In 2024, the median AI unicorn reached a $1B+ valuation in just 2 years with a team of 203 employees. 

That’s compared to 9 years and twice the headcount for non-AI unicorns.

The headcounts of these AI unicorns — and the speed at which they’re maturing — point to AI’s ability to help them automate, scale quickly, and attract investor attention early. 

Discover how AI is reshaping the unicorn landscape in our latest report.

Go with the workflow

We recently announced this year’s Digital Health 50 — our list of the most promising digital health startups in the world. 

Over a third (19) of these companies are focused on streamlining clinical and administrative tasks.

The surge of automation solutions here signals that workflow efficiency has emerged as a key priority for healthcare organizations, particularly as they’ve grappled with staffing shortages.

Also rising up to address these shortages? Robots. Learn more in this report.

Come and get ‘em

Liquid biopsies are blood tests that can detect the presence of cancer, track treatment response, and detect resistance early.

Diagnostics incumbents — like Quest Diagnostics and Veracyte — are scooping up startups in the space to expand their capabilities.

We analyzed the liquid biopsy landscape below to fast-track the identification of high-potential acquisition targets.

Discover the top 5 in this research brief.

CB Insights customers can instantly pull up the top 5 using this advanced search.

I love you.

Anand

@asanwal 

Co-Founder & Exec Chair

P.S. Want to learn more about how we selected this year’s Digital Health 50? Dive in with our analysts in this briefing.

Get started with CB Insights

CB Insights' emerging technology insights platform provides all the

analysis and data from this newsletter. Our data is the easiest way to discover and respond to emerging tech. 

Was this email forwarded to you? Sign up here